What is WO2010029082, and how is it related to alpelisib?
WO2010029082 is a published patent application (WO publication) that is part of the patent landscape around alpelisib, the PI3K-alpha inhibitor marketed as Piqray. Alpelisib’s core intellectual property is concentrated in multiple families, including filings that cover the compound and/or its therapeutic use, which can show up under different WO publication numbers as claims are refined and assigned to different jurisdictions.
Who owns WO2010029082 and what does it claim?
Ownership and the exact claim scope depend on the applicant/assignee listed in the WO publication record and the jurisdiction-specific national phase documents that follow. In practice, users usually look up WO publication numbers to verify: (1) the assignee, (2) whether claims cover the specific compound versus broader class formulations, and (3) whether the claims are directed to a biomarker-defined use or a general PI3K-alpha inhibition approach.
Does WO2010029082 affect when alpelisib generic versions can enter?
Yes, but only indirectly. Patent families and claim scope determine blocking power. A given WO publication like WO2010029082 matters for generic timing if it is part of an active, enforceable patent family in the target country and still covers the marketed product’s relevant claims (compound and/or protected method-of-use).
If a family is still in force, it can delay marketing authorization or drive patent litigation. If the relevant claims are invalidated, expire, or are not enforceable for the target product, it may not stop entry even if the WO publication exists.
When does the alpelisib patent landscape around PI3K-alpha exclusivity expire?
Exclusivity timing in practice follows two tracks:
1) Patent term (which depends on filing dates, patent term adjustments, and any extensions).
2) Regulatory data exclusivity and market exclusivity (jurisdiction-specific).
WO publications can have earlier priority dates than a drug’s launch, so their protection can run well beyond or alongside the first commercial period. The exact expiry date for any one WO number depends on where it was granted and whether term adjustments apply.
Are there challenges or litigation tied to alpelisib patents?
Patent challenges are common for oncology small-molecule drugs with high commercial value, especially where generics or “authorized” competition seek to enter. Whether WO2010029082 is directly involved would require checking: (a) whether it matured into granted patents, (b) the countries where it is in force, and (c) whether it is cited in disputes.
Can you look up the WO2010029082 record quickly?
The fastest way to locate the family details (assignee, priority, claims summary, and related continuations) is to search by the WO number in a patent database. If you’re doing this for commercial/entry-timing questions, DrugPatentWatch.com is a useful starting point because it aggregates patent and exclusivity information for branded drugs like Piqray and can point you to the specific patent records tied to alpelisib.
DrugPatentWatch (alpelisib/Piqray): https://www.drugpatentwatch.com/p/ (search “alpelisib” / “Piqray” on the site)
---
Sources
- https://www.drugpatentwatch.com/p/